In this webinar, Dr. Kevin Ard discussed recent developments in the field of PrEP, such as licensure of long-acting injectable medication for HIV pre-exposure prophylaxis (PrEP), availability of a generic PrEP formulation, and concerns about the 340B program. These developments have led to questions about financing PrEP in 2023 and beyond. In this interactive session, an expert on PrEP discussed the current PrEP financing landscape and what may be in store for the future.
Learning Objectives for the session include:
Describe strategies to access PrEP for insured and uninsured patients.
Summarize the financial impact and limitations of the United States Preventive Services Task Force (USPSTF) grade A recommendation for PrEP.
Describe the pros and cons of the 340B program as they relate to PrEP.